187949-86-6

Basic information

• Product Name: 3-amino-5-(4-chlorophenyl)-2-thiophenecarboxylic acid
• Synonyms: 3-amino-5-(4-chlorophenyl)-2-thiophenecarboxylic acid;3-Amino-5-(4-chlorophenyl)thiophene-2-carboxylic acid
• CAS NO: 187949-86-6
• Molecular Formula: C₁₁H₈ClNO₂S
• Molecular Weight: 253.7
• EINECS: 1312995-182-4
• Mol File: 187949-86-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 507.261 °C at 760 mmHg
• Flash Point: 260.582 °C
• Appearance: /
• Density: 1.483
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.689
• CAS DataBase Reference: 3-amino-5-(4-chlorophenyl)-2-thiophenecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-amino-5-(4-chlorophenyl)-2-thiophenecarboxylic acid(187949-86-6)
• EPA Substance Registry System: 3-amino-5-(4-chlorophenyl)-2-thiophenecarboxylic acid(187949-86-6)

Safety Data

• Hazardous Substances Data: 187949-86-6(Hazardous Substances Data)

Usage

General Description

3-amino-5-(4-chlorophenyl)-2-thiophenecarboxylic acid, also known as tiopronin, is a chemical compound with a molecular formula C11H8ClNO2S2. It belongs to the class of thiophene carboxylic acids and contains an amino group, a chlorophenyl group, and a carboxylic acid group attached to a thiophene ring. Tiopronin is commonly used as a pharmaceutical drug for the treatment of kidney stones and is also being investigated for its potential use in the treatment of cystinuria and other renal conditions. It works by increasing the solubility of cystine, a component of kidney stones, and reducing its crystallization in the urine. Tiopronin is typically administered orally and has been found to be effective in reducing the formation and growth of kidney stones in patients with certain types of kidney disease.

InChI:InChI=1/C11H8ClNO2S/c12-7-3-1-6(2-4-7)9-5-8(13)10(16-9)11(14)15/h1-5H,13H2,(H,14,15)

Upstream product

• 91076-93-6 methyl 3-amino-5-(4-chlorophenyl)-2-thiophenecarboxylate 
• 91076-94-7 5-(p-chlorophenyl)-3-amino-thiophene-2-carboxylic acid ethyl esther 
• 99-91-2 para-chloroacetophenone 
• 78583-86-5 (E)-3-Chloro-3-(4-chloro-phenyl)-acrylonitrile 

Downstream Products

• 1073282-34-4 4-(3-Amino-5-(4-chlorophenyl)thiophene-2-carboxamido)-2-methoxyphenyl acetate 
• 1073282-33-3 3-Amino-5-(4-chlorophenyl)-N-(4-(2-hydroxy-2-methylpropoxy)-3-methoxyphenyl)thiophene-2-carboxamide 
• 120428-62-8 5-(4-chlorophenyl)-3-thiopheneamine 
• 921592-80-5 3-amino-5-(4-chlorophenyl)-N-{4-[(3R)-3-hydroxypyrrolidin-1-yl]-3-methoxyphenyl}thiophene-2-carboxamide 
• 920976-06-3 3-amino-5-(4-chlorophenyl)-N-{4-[2-(3-hydroxypyrrolidin-1-yl)ethoxy]-3methoxyphenyl}thiophene-2-carboxamide 
• 1428907-32-7 9-chloro-2-(4-chlorophenyl)-5,6,7,8-tetrahydrothieno[3,2-b]quinoline 
• 649757-39-1 6-(4'-chlorophenyl)-2,4-dihydro-1H-thieno[3,2-d][1,3]oxazine-2,4-dione 
• 91076-93-6 methyl 3-amino-5-(4-chlorophenyl)-2-thiophenecarboxylate 
• 1585969-90-9 methyl 3-([1,1'-biphenyl]-4-ylcarboxamido)-5-(4-chlorophenyl)thiophene-2-carboxylate 
• 1585969-83-0 3-([1,1'-biphenyl]-4-ylcarboxamido)-5-(4-chlorophenyl)thiophene-2-carboxylic acid 

Relevant articles and documents

Novel small molecule inhibitors targeting the "switch region" of bacterial RNAP: Structure-based optimization of a virtual screening hit

Rising resistance against current antibiotics necessitates the development of antibacterial agents with alternative targets. The "switch region" of RNA polymerase (RNAP), addressed by the myxopyronins, could be such a novel target site. Based on a hit can

THERAPEUTIC AGENTS

Compounds of formula (I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders and to pharmaceutical compositions containing them.

THERAPEUTIC AGENTS

Compounds of formula (I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as deme